Myrelez (Lanreotide Acetate)

Lanreotide acetate mimics the natural hormone somatostatin. It binds to somatostatin receptors on pituitary and neuroendocrine cells, inhibiting adenylate cyclase and reducing cyclic AMP, which suppresses the release of growth hormone and other peptide hormones.

The dosing regimen for Myrelez is individualized. A qualified prescriber determines the appropriate dose, frequency, and duration based on the patient’s condition, response, and clinical guidelines.

Safety data in pregnancy and lactation are limited. Myrelez should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by the treating physician.

To request Myrelez, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and necessary import documentation.

The primary alternative is octreotide, another somatostatin analogue. Both agents suppress hormone secretion, but lanreotide has a longer dosing interval (often every 4 weeks) compared with octreotide’s more frequent dosing, which can improve convenience for some patients.

Myrelez should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability.

Myrelez is given as a subcutaneous injection, typically by a healthcare professional. The injection is administered into the abdominal wall or thigh, following aseptic technique and the specific instructions provided by the prescriber.

Serious risks include gallstone formation, acute pancreatitis, severe hyperglycemia, and allergic reactions such as anaphylaxis. Patients should be monitored for abdominal pain, unexplained fever, skin rash, or signs of infection, and seek immediate medical attention if these occur.

Myrelez is contraindicated in patients with known hypersensitivity to lanreotide or any of its excipients. Caution is advised for individuals with severe hepatic impairment, uncontrolled diabetes, or active gallbladder disease, and it should be avoided in pregnant women unless clearly indicated.